Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Allogene Therapeutics, Inc., a clinical-stage biotechnology company
pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies
for cancer, today announced it has filed an S-1 registration statement
with the Securities and Exchange Commission (“SEC”) relating to a
proposed offering of its common stock. All shares of common stock to be
sold in the offering will be offered by Allogene. The number of shares
to be offered and the price range for the proposed offering have not yet
been determined. Allogene has applied to list its stock for trading on
the NASDAQ under the symbol “ALLO.”

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company,
LLC and Jefferies LLC are acting as the joint book-running managers for
the proposed offering.

A registration statement relating to these securities has been filed
with the SEC, but has not yet become effective. These securities may not
be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy nor
shall there be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such
state or jurisdiction.

The offering will be made only by means of a prospectus. When available,
copies of the preliminary prospectus relating to and describing the
terms of the offering may be obtained from:

  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West
    Street, New York, New York 10282, via telephone: 1-866-471-2526, or
    via email: prospectus-ny@ny.email.gs.com;
    or
  • J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
    Long Island Avenue, Edgewood, NY 11717, or via telephone:
    1-866-803-9204; or
  • Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long
    Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by
    telephone at 1-631-274-2806; or
  • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
    Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at
    1-877-547-6340, or by email at Prospectus_Department@Jefferies.com

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a
clinical stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T-cell (CAR T) therapies for cancer.

Contacts

Allogene Media/Investor Contact:
Christine Cassiano,
714-552-0326
Chief Communications Officer
Christine.Cassiano@allogene.com